Daehwa wins patent for oral paclitaxel

Published: 2012-02-24 06:56:00

Updated: 2012-02-24 06:56:00

Daehwa Pharmaceutical said Wednesday that the company won an U.S. patent covering the oral form of widely used cancer drug paclitaxel, which is normally administered through injection.

The patent covers "composition for solublization of paclitaxel and preparation method thereof that make it p...

Fees

- Email service daily and homepage access.

$300 per month. ($3,240 per year)
5 Email holders per each company.
Anual contract base.

Latest News

Which are outstanding tetravalent vaccines even for the young?

Disease treated the most with clinical trial drugs is respiratory disorder like lung cancer

Who will be the next Pharmaceutical Safety Bureau Director?

Celltrion completes clinical trials for Remsima SC for European approval

Sales listed pharmas made in the first half of the year

TOP

BACK